These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3766155)

  • 1. The influence of surgery on the elimination kinetics of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HO; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Jul; 59(1):86-8. PubMed ID: 3766155
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacokinetics and protein binding of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HP; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):282-8. PubMed ID: 3716823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ethanol intake on disopyramide elimination by healthy volunteers.
    Olsen H; Bredesen JE; Lunde PK
    Eur J Clin Pharmacol; 1983; 25(1):103-5. PubMed ID: 6617710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atenolol inhibits the elimination of disopyramide.
    Bonde J; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1985; 28(1):41-3. PubMed ID: 3987784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide elimination in the isolated perfused rat liver.
    Lennard MS; Tucker GT; Woods HF; Rose DA; Barrow A
    Xenobiotica; 1984 Nov; 14(11):885-92. PubMed ID: 6506761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
    Giacomini KM; Blaschke TF
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective gastrointestinal clearance of disopyramide in rabbits treated with activated charcoal.
    Huang JD
    J Pharm Sci; 1988 Nov; 77(11):959-62. PubMed ID: 3225758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of disopyramide in decreased hepatic function.
    Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of age and smoking on the elimination of disopyramide.
    Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.